<code id='D1BED4A23D'></code><style id='D1BED4A23D'></style>
    • <acronym id='D1BED4A23D'></acronym>
      <center id='D1BED4A23D'><center id='D1BED4A23D'><tfoot id='D1BED4A23D'></tfoot></center><abbr id='D1BED4A23D'><dir id='D1BED4A23D'><tfoot id='D1BED4A23D'></tfoot><noframes id='D1BED4A23D'>

    • <optgroup id='D1BED4A23D'><strike id='D1BED4A23D'><sup id='D1BED4A23D'></sup></strike><code id='D1BED4A23D'></code></optgroup>
        1. <b id='D1BED4A23D'><label id='D1BED4A23D'><select id='D1BED4A23D'><dt id='D1BED4A23D'><span id='D1BED4A23D'></span></dt></select></label></b><u id='D1BED4A23D'></u>
          <i id='D1BED4A23D'><strike id='D1BED4A23D'><tt id='D1BED4A23D'><pre id='D1BED4A23D'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:leisure time    Page View:47
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In